Regulation of endometrial cancer cell growth by insulin-like growth factors and the luteinizing hormone-releasing hormone antagonist SB-75

Dita Kleinman, Charles Roberts, Derek LeRoith, Andrew V. Schally, Joseph Levy, Yoav Sharoni

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

The involvement of IGFs in growth regulation of the Ishikawa endometrial tumor cell line and the possible interference of LH-RH analogues with a potential autocrine or paracrine loop involving IGFs was evaluated. The mitogenic effects of IGF-I, IGF-II, and insulin were compared. IGF-I was found to be 3-fold more potent than IGF-II and 30-fold more potent than insulin, suggesting that the effects of these growth factors are mediated by the IGF-I receptor. Ishikawa endometrial cancer cells secrete IGF-II, but not IGF-I, and insulin (1 μM) stimulates IGF-II release. The LH-RH antagonist [Ac-d-Nal(2)1, d-Phe(4Cl)2, d-Pal(3)3, d-Cit6, d-Ala10]-GnRH (SB-75, CETRORELIX) inhibited basal and IGF-induced growth. Moreover, this antagonist almost completely inhibited IGF-II release from Ishikawa cells, while having no significant effect on the number or affinity of IGF-I binding sites. Inhibition of IGF-II release occurred at a lower SB-75 concentration than that needed for a reduction in cell number. The ED50 of SB-75 for IGF-II release was 0.3 μM as compared to 1.5 μm concentration which is required for reduction in cell number, suggesting that inhibition of growth factor release precedes cell growth inhibition. We conclude that the LH-RH antagonist SB-75 can inhibit the growth of endometrial cancer cells by interfering with the autocrine action of IGF-II and also by directly inhibiting the growth-stimulatory effects of IGFs, probably through effects on a post-receptor mechanism.

Original languageEnglish (US)
Pages (from-to)91-98
Number of pages8
JournalRegulatory Peptides
Volume48
Issue number1-2
DOIs
StatePublished - Oct 20 1993
Externally publishedYes

Fingerprint

Hormone Antagonists
Insulin-Like Growth Factor II
Cell growth
Somatomedins
Endometrial Neoplasms
Gonadotropin-Releasing Hormone
Growth
Insulin-Like Growth Factor I
Cells
Insulin
Intercellular Signaling Peptides and Proteins
Cell Count
IGF Type 1 Receptor
cetrorelix
Tumor Cell Line
Tumors
Binding Sites

Keywords

  • Antagonist
  • Cancer cell growth
  • Insulin-like growth factor
  • Luteinizing hormone-releasing hormone

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology
  • Physiology
  • Neuroscience(all)

Cite this

Regulation of endometrial cancer cell growth by insulin-like growth factors and the luteinizing hormone-releasing hormone antagonist SB-75. / Kleinman, Dita; Roberts, Charles; LeRoith, Derek; Schally, Andrew V.; Levy, Joseph; Sharoni, Yoav.

In: Regulatory Peptides, Vol. 48, No. 1-2, 20.10.1993, p. 91-98.

Research output: Contribution to journalArticle

Kleinman, Dita ; Roberts, Charles ; LeRoith, Derek ; Schally, Andrew V. ; Levy, Joseph ; Sharoni, Yoav. / Regulation of endometrial cancer cell growth by insulin-like growth factors and the luteinizing hormone-releasing hormone antagonist SB-75. In: Regulatory Peptides. 1993 ; Vol. 48, No. 1-2. pp. 91-98.
@article{278b2e46e0974e0496f6709e02ecc963,
title = "Regulation of endometrial cancer cell growth by insulin-like growth factors and the luteinizing hormone-releasing hormone antagonist SB-75",
abstract = "The involvement of IGFs in growth regulation of the Ishikawa endometrial tumor cell line and the possible interference of LH-RH analogues with a potential autocrine or paracrine loop involving IGFs was evaluated. The mitogenic effects of IGF-I, IGF-II, and insulin were compared. IGF-I was found to be 3-fold more potent than IGF-II and 30-fold more potent than insulin, suggesting that the effects of these growth factors are mediated by the IGF-I receptor. Ishikawa endometrial cancer cells secrete IGF-II, but not IGF-I, and insulin (1 μM) stimulates IGF-II release. The LH-RH antagonist [Ac-d-Nal(2)1, d-Phe(4Cl)2, d-Pal(3)3, d-Cit6, d-Ala10]-GnRH (SB-75, CETRORELIX) inhibited basal and IGF-induced growth. Moreover, this antagonist almost completely inhibited IGF-II release from Ishikawa cells, while having no significant effect on the number or affinity of IGF-I binding sites. Inhibition of IGF-II release occurred at a lower SB-75 concentration than that needed for a reduction in cell number. The ED50 of SB-75 for IGF-II release was 0.3 μM as compared to 1.5 μm concentration which is required for reduction in cell number, suggesting that inhibition of growth factor release precedes cell growth inhibition. We conclude that the LH-RH antagonist SB-75 can inhibit the growth of endometrial cancer cells by interfering with the autocrine action of IGF-II and also by directly inhibiting the growth-stimulatory effects of IGFs, probably through effects on a post-receptor mechanism.",
keywords = "Antagonist, Cancer cell growth, Insulin-like growth factor, Luteinizing hormone-releasing hormone",
author = "Dita Kleinman and Charles Roberts and Derek LeRoith and Schally, {Andrew V.} and Joseph Levy and Yoav Sharoni",
year = "1993",
month = "10",
day = "20",
doi = "10.1016/0167-0115(93)90338-9",
language = "English (US)",
volume = "48",
pages = "91--98",
journal = "Regulatory Peptides",
issn = "0167-0115",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - Regulation of endometrial cancer cell growth by insulin-like growth factors and the luteinizing hormone-releasing hormone antagonist SB-75

AU - Kleinman, Dita

AU - Roberts, Charles

AU - LeRoith, Derek

AU - Schally, Andrew V.

AU - Levy, Joseph

AU - Sharoni, Yoav

PY - 1993/10/20

Y1 - 1993/10/20

N2 - The involvement of IGFs in growth regulation of the Ishikawa endometrial tumor cell line and the possible interference of LH-RH analogues with a potential autocrine or paracrine loop involving IGFs was evaluated. The mitogenic effects of IGF-I, IGF-II, and insulin were compared. IGF-I was found to be 3-fold more potent than IGF-II and 30-fold more potent than insulin, suggesting that the effects of these growth factors are mediated by the IGF-I receptor. Ishikawa endometrial cancer cells secrete IGF-II, but not IGF-I, and insulin (1 μM) stimulates IGF-II release. The LH-RH antagonist [Ac-d-Nal(2)1, d-Phe(4Cl)2, d-Pal(3)3, d-Cit6, d-Ala10]-GnRH (SB-75, CETRORELIX) inhibited basal and IGF-induced growth. Moreover, this antagonist almost completely inhibited IGF-II release from Ishikawa cells, while having no significant effect on the number or affinity of IGF-I binding sites. Inhibition of IGF-II release occurred at a lower SB-75 concentration than that needed for a reduction in cell number. The ED50 of SB-75 for IGF-II release was 0.3 μM as compared to 1.5 μm concentration which is required for reduction in cell number, suggesting that inhibition of growth factor release precedes cell growth inhibition. We conclude that the LH-RH antagonist SB-75 can inhibit the growth of endometrial cancer cells by interfering with the autocrine action of IGF-II and also by directly inhibiting the growth-stimulatory effects of IGFs, probably through effects on a post-receptor mechanism.

AB - The involvement of IGFs in growth regulation of the Ishikawa endometrial tumor cell line and the possible interference of LH-RH analogues with a potential autocrine or paracrine loop involving IGFs was evaluated. The mitogenic effects of IGF-I, IGF-II, and insulin were compared. IGF-I was found to be 3-fold more potent than IGF-II and 30-fold more potent than insulin, suggesting that the effects of these growth factors are mediated by the IGF-I receptor. Ishikawa endometrial cancer cells secrete IGF-II, but not IGF-I, and insulin (1 μM) stimulates IGF-II release. The LH-RH antagonist [Ac-d-Nal(2)1, d-Phe(4Cl)2, d-Pal(3)3, d-Cit6, d-Ala10]-GnRH (SB-75, CETRORELIX) inhibited basal and IGF-induced growth. Moreover, this antagonist almost completely inhibited IGF-II release from Ishikawa cells, while having no significant effect on the number or affinity of IGF-I binding sites. Inhibition of IGF-II release occurred at a lower SB-75 concentration than that needed for a reduction in cell number. The ED50 of SB-75 for IGF-II release was 0.3 μM as compared to 1.5 μm concentration which is required for reduction in cell number, suggesting that inhibition of growth factor release precedes cell growth inhibition. We conclude that the LH-RH antagonist SB-75 can inhibit the growth of endometrial cancer cells by interfering with the autocrine action of IGF-II and also by directly inhibiting the growth-stimulatory effects of IGFs, probably through effects on a post-receptor mechanism.

KW - Antagonist

KW - Cancer cell growth

KW - Insulin-like growth factor

KW - Luteinizing hormone-releasing hormone

UR - http://www.scopus.com/inward/record.url?scp=0027433462&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027433462&partnerID=8YFLogxK

U2 - 10.1016/0167-0115(93)90338-9

DO - 10.1016/0167-0115(93)90338-9

M3 - Article

C2 - 8265821

AN - SCOPUS:0027433462

VL - 48

SP - 91

EP - 98

JO - Regulatory Peptides

JF - Regulatory Peptides

SN - 0167-0115

IS - 1-2

ER -